Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Biotech Acquisition Company (BAC) was a Special Purpose Acquisition Company (SPAC) that completed its $230 million IPO in January 2021 to pursue a business combination in the healthcare sector. After a terminated merger agreement with Blade Therapeutics in June 2022, the company liquidated in February 2023.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Biotech Acquisition Company.